Abstract 67P
Background
BP02 is a trastuzumab biosimilar in development. This study evaluated equivalence of BP02 to reference trastuzumab (RT: Herceptin-EU) in HER2+ve metastatic breast cancer (MBC).
Methods
In this randomized, double-blind, parallel-group, active-controlled, multicentric, phase 3 equivalence trial, we recruited women aged 18-75 yrs with histologically/ cytologically confirmed HER2+ve, locally recurrent or MBC with systemic metastasis, from 59 sites in India. Inclusion criteria were at least one measurable lesion (RECIST 1.1), ECOG performance status of ≤2, probable life expectancy of ≥18 mths, LVEF ≥55%, adequate renal, hepatic, and hematological functions. Exclusion criteria included contralateral breast cancer, cancer of any other site, metastases to brain and spinal cord; previous exposure to any prior therapy to metastatic disease; serious cardiac illness and known hypersensitivity to trastuzumab. We randomly allocated patients 1:1 stratified by ER and PR status to receive BP02 or RT (8mg/kg loading dose on day 1 of cycle 1, 6mg/kg on day 1 of cycles 2-8, each cycle lasting 3 wks) combined with docetaxel (75mg/m2 on day 1 of cycles 1-8) [induction phase]. Participants with complete or partial response, or stable disease at end of induction phase continued the study drug until disease progression or treatment discontinuation [maintenance phase]. Participants and investigators were masked to treatment until study completion. The primary efficacy endpoint was objective response rate (ORR) as per RECIST 1.1. Results of induction phase are presented.
Results
Between 23-Sep-2020 and 16-Sep-2022, we randomly allocated 690 patients (n=345 each to BP02 and RT). In the ITT population, similar proportion of patients achieved ORR with BP02 (n=231, 67.0%, 95% CI 62.0, 71.9) and RT (n=238, 69.0%, 95% CI 64.1, 73.9). 95% CI of risk difference (-2.03, 95% CI -9.15, 5.09) was within the equivalence margins of ±13%. 90% CI of risk ratio (0.97, 90% CI 0.89, 1.06) was within the equivalence margins of (0.80, 1.25). TEAEs were seen in 58% and 60.3% patients; TEAEs leading to treatment withdrawal were reported in 2.9% and 3.2% patients, with BP02 and RT respectively.
Conclusions
BP02 showed equivalent efficacy and similar safety profile to RT.
Clinical trial identification
CTRI/2020/04/024456.
Editorial acknowledgement
Dr Vallish BN from MarksMan Healthcare Communications, India provided editorial assistance in writing of the abstract.
Legal entity responsible for the study
Curateq Biologics Private Limited, Hyderabad, India.
Funding
Curateq Biologics Private Limited, Hyderabad, India.
Disclosure
A. Prajapati, D. Dadke: Financial Interests, Personal, Full or part-time Employment: Curateq biologics. R.K. Kothari: Financial Interests, Personal, Financially compensated role: Zydus Pharmaceuticals, AstraZeneca, Glenmark, Novartis, Emcure, Fresenius Kabi, Bard Peripheral Vascular, Pfizer, Alkem Laboratories, Roche; Financial Interests, Institutional, Financially compensated role: Cipla, Merck, Celon Pharma, Bristol Myers Squibb Foundation; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Institutional, Research Funding: Zydus Pharmaceuticals, Lambda Therapeutic Research, Axis Clinicals, Reliance Life Sciences. All other authors have declared no conflicts of interest.
Resources from the same session
623P - Advances in methylation analysis of liquid biopsy in early cancer detection of colorectal and lung cancer
Presenter: Sam Martin
Session: Poster Display
Resources:
Abstract
624P - Pan-cancer single-cell isoform atlas: Unraveling isoform dynamics in cancer immunotherapy
Presenter: Lu Pan
Session: Poster Display
Resources:
Abstract
625P - The association of tumor marker concentration and air pollution in cancer survivors and the general population
Presenter: Kyae Hyung Kim
Session: Poster Display
Resources:
Abstract
626P - Percentage of cancer patients undergoing adjusted targeted therapy after ctDNA testing: Insights from a tertiary hospital experience
Presenter: Jisook Yim
Session: Poster Display
Resources:
Abstract
627P - Racial disparities in synchronous and metachronous colorectal and prostate cancer: SEER based study 2000-2020
Presenter: Taha Nagib
Session: Poster Display
Resources:
Abstract